## Highlights of This Issue 6393

### SPECIAL FEATURES

#### CCR Translations

- **6395** Assessing Iron Overload: Are We There Yet?  
  Paul C. Kruger, Michael F. Leahy, and John K. Olynyk  
  See article p. 6460

- **6398** Improving Publication Rates of Biomarker Results from Cancer Trials  
  Robert Iannone  
  See article p. 6478

#### Molecular Pathways

- **6400** Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement  
  Benjamin H. Lok and Simon N. Powell

#### Review

- **6407** \[\text{p53 Arg22Pro Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis}\]  
  Steven Habbous, Vincent Pang, Lawson Eng, Wei Xu, Goldie Kurtz, Fei-Fei Liu, Helen Mackay, Eitan Amir, and Geoffrey Liu

#### HUMAN CANCER BIOLOGY

- **6416** Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9  
  Mei-Hsuan Lu, Chao-Cheng Huang, Mei-Ren Pan, Hong-Hwa Chen, and Wen-Chun Hung

- **6426** Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping  
  Julia D. Wallukhle, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Marijelena Pierobon, Jianghong Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Waldhor, Heinz Höller, Laura Esserman on behalf of the I-SPY 1 TRIAL Investigators, Lance A. Lioitta, Karl-Friedrich Becker, and Emanuel F. Petricoin III

### CANCER THERAPY: PRECLINICAL

- **6436** Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies  
  Koji Tamada, Degui Geng, Yukimi Sakoda, Navneeta Bansal, Ratika Srivastava, Zhaoyang Li, and Eduardo Davila

- **6446** Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma  
  Martin K. Hunn, Kathryn J. Farrand, Kate W.R. Broadley, Robert Weinkove, Peter Ferguson, Rose J. Miller, Cameron S. Field, Troels Petersen, Melanie J. McConnell, and Ian F. Herrmans

#### IMAGING, DIAGNOSIS, PROGNOSIS

- **6460** MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation  
  Martin Wermke, Anne Schmidt, Jan Moritz Middeke, Katja Sockel, Malte von Bonin, Claudia Schöenefeldt, Sabine Mair, Verena Plodeck, Michael Laniado, Günter Weiss, Johannes Schetelig, Gerhard Ehninger, Igor Theurl, Martin Bornhauser, and Uwe Platzbecker  
  See commentary p. 6395

- **6469** Combratstatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging  
  Thomas Nielsen, Lise Bentzen, Michael Pedersen, Trine Tramm, Paul F.J.W. Rijken, Johan Bussink, Michael R. Horsman, and Leif Østergaard
CANCER THERAPY: CLINICAL

Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials
Georgina A. Freeman and Jonathan Kimmelman
See commentary p. 6398

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Paola Filipazzi, Lorenzo Pilla, Luigi Mariani, Roberto Patuzzo, Chiara Castelli, Chiara Carnisacchi, Andrea Maurichi, Agata Cova, Gianluigi Rigamonti, Felicetta Giardino, Annabella Di Florio, Marco Asiol, Paola Frati, Gloria Sovena, Paola Squarzina, Michele Maio, Riccardo Danielli, Vanna Chiarion-Sileni, Antonello Villa, Claudia Lombardo, Gabrina Tragni, Mario Santinami, Giorgio Parmiani, and Licia Rivoltini

A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Stanley B. Kaye, Louis Fehrenbacher, Robert Holloway, Ammon Amit, Beth Karlan, Brian Slomovitz, Paul Sabbatini, Ling Fu, Robert L. Yau, Il Sung Chang, and Josina C. Reddy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Yunfeng Cui, Jacqueline A. Brosnan, Amanda L. Blackford, Surojit Sur, Ralph H. Hruban, Kenneth W. Kimzler, Bert Vogelstein, Anirban Maitra, Luis A. Diaz Jr, Christine A. Iacobuzio-Donahue, and James R. Eshleman

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

ACKNOWLEDGMENT TO REVIEWERS

ABOUT THE COVER

Expression of GFP-tagged PROX1 in colon cancer cells reduced E-cadherin and induced epithelial–mesenchymal transition. We found that PROX1 activated miR-9 expression to attenuate E-cadherin protein posttranscriptionally. Results of this study provide a molecular basis by which PROX1 promotes tumorigenesis of colon cancer. For details, see the article by Lu and colleagues on page 6416 of this issue.